Anbio Biotechnology
NNNNHealthcareNASDAQMedical Instruments & Supplies · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Anbio Biotechnology focuses on Medical Instruments & Supplies services and products. Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. Valued at $416.5M, NNNN is a small-cap name in its sector. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Market Cap
$416.5M
Beta
—
P/E (TTM)
63.27
P/E (Fwd)
—
EPS (TTM)
$0.15
EPS (Fwd)
—
ROE
27.1%
ROA
14.7%
Cash
$11.9M
Total Debt
$0
Free CF
-$9.6M
52W Change
-79.8%
Annual Financials
Cash vs Debt
Anbio Biotechnology reports $11.9M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$9.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 27.1% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 14.7% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $23.5M to $8.6M.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. At over 50x earnings, NNNN carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Anbio Biotechnology and its sector.